Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics

View ORCID ProfileUsman Arshad, Henry Pertinez, Helen Box, Lee Tatham, View ORCID ProfileRajith KR Rajoli, View ORCID ProfilePaul Curley, View ORCID ProfileMegan Neary, Joanne Sharp, View ORCID ProfileNeill J Liptrott, Anthony Valentijn, Christopher David, View ORCID ProfileSteve P Rannard, Paul O’Neill, View ORCID ProfileGhaith Aljayyoussi, View ORCID ProfileShaun Pennington, Stephen A Ward, David J Back, View ORCID ProfileSaye H Khoo, Patrick G Bray, View ORCID ProfileGiancarlo Biagini, View ORCID ProfileAndrew Owen
doi: https://doi.org/10.1101/2020.04.16.20068379
Usman Arshad
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Usman Arshad
Henry Pertinez
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Box
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee Tatham
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajith KR Rajoli
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rajith KR Rajoli
Paul Curley
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Curley
Megan Neary
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Megan Neary
Joanne Sharp
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neill J Liptrott
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Neill J Liptrott
Anthony Valentijn
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher David
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve P Rannard
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steve P Rannard
Paul O’Neill
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ghaith Aljayyoussi
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ghaith Aljayyoussi
Shaun Pennington
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shaun Pennington
Stephen A Ward
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J Back
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saye H Khoo
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Saye H Khoo
Patrick G Bray
4Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giancarlo Biagini
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giancarlo Biagini
Andrew Owen
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew Owen
  • For correspondence: aowen{at}liverpool.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the ability of these drugs to achieve target plasma and lung concentrations following approved dosing in humans. Moreover, most publications have focussed on 50% maximum effective concentrations (EC50), which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration-response curve between drugs. Accordingly, in vitro anti-SARS-CoV-2 activity data was digitised from all available publications up to 13th April 2020 and used to recalculate an EC90 value for each drug. EC90 values were then expressed as a ratio to the achievable maximum plasma concentrations (Cmax) reported for each drug after administration of the approved dose to humans (Cmax/EC90 ratio). Only 14 of the 56 analysed drugs achieved a Cmax/EC90 ratio above 1 meaning that plasma Cmax concentrations exceeded those necessary to inhibit 90% of SARS-CoV-2 replication. A more in-depth assessment of the putative agents tested demonstrated that only nitazoxanide, nelfinavir, tipranavir (boosted with ritonavir) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval at their approved human dose. For all drugs reported, the unbound lung to plasma tissue partition coefficient (KpUlung) was also simulated and used along with reported Cmax and fraction unbound in plasma to derive a lung Cmax/EC50 as a better indicator of potential human efficacy (lung Cmax/EC90 ratio was also calculable for a limited number of drugs). Using this parameter hydroxychloroquine, chloroquine, mefloquine, atazanavir (boosted with ritonavir), tipranavir (boosted with ritonavir), ivermectin, azithromycin and lopinavir (boosted with ritonavir) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50. This analysis was not possible for nelfinavir because insufficient data were available to calculate KpUlung but nitozoxanide and sulfadoxine were also predicted to exceed their reported EC50 by 3.1- and 1.5-fold in lung, respectively. The antiviral activity data reported to date have been acquired under different laboratory conditions across multiple groups, applying variable levels of stringency. However, this analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds which are unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC90 values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no funding for this work

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 22, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith KR Rajoli, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Paul O’Neill, Ghaith Aljayyoussi, Shaun Pennington, Stephen A Ward, David J Back, Saye H Khoo, Patrick G Bray, Giancarlo Biagini, Andrew Owen
medRxiv 2020.04.16.20068379; doi: https://doi.org/10.1101/2020.04.16.20068379
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith KR Rajoli, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Paul O’Neill, Ghaith Aljayyoussi, Shaun Pennington, Stephen A Ward, David J Back, Saye H Khoo, Patrick G Bray, Giancarlo Biagini, Andrew Owen
medRxiv 2020.04.16.20068379; doi: https://doi.org/10.1101/2020.04.16.20068379

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)